Published in Med Sci Monit on June 04, 2016
[Prostate artery embolization (PAE) : Technique and results]. Radiologe (2017) 0.75
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA (2006) 4.15
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol (2008) 2.58
Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ (2003) 2.29
Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol (2006) 2.15
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int (2004) 2.11
Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications. J Am Osteopath Assoc (2008) 1.61
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol (2008) 1.55
Diagnosis and management of benign prostatic hyperplasia. Am Fam Physician (2008) 1.49
Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK. Int J Clin Pract (2008) 1.46
State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology (2004) 1.17
Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev (2012) 1.08
Treatment options for benign prostatic hyperplasia in older men. Med Sci Monit (2008) 1.07
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol (1998) 1.07
Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol (2000) 1.02
Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging (1997) 1.01
Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis (2011) 0.99
Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs (1995) 0.95
The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int (2001) 0.95
Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) (2007) 0.92
Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study. Clin Drug Investig (2004) 0.92
A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int (2003) 0.90
Identification of alpha 1-adrenoceptor subtypes in the human prostatic urethra. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.88
Alpha adrenoceptor antagonists in the year 2000: is there anything new? Curr Opin Urol (2001) 0.87
Various treatment options for benign prostatic hyperplasia: A current update. J Midlife Health (2012) 0.86
Quantitative quality control during urodynamic studies with TVRs for cystometry in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int Urol Nephrol (2014) 0.86
Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol (2000) 0.86
Interactions between prostate volume, filling cystometric estimated parameters, and data from pressure-flow studies in 565 men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Neurourol Urodyn (2001) 0.85
alpha(1)-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis (2000) 0.83
Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile. BJU Int (2005) 0.81
Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration. BJU Int (2010) 0.80
Current status of research on prostate-selective alpha 1-antagonists. Br J Urol (1998) 0.78
Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates. BJU Int (2015) 0.78
Expression of Heat Shock Protein 27 in Benign Prostatic Hyperplasia with Chronic Inflammation. Med Sci Monit (2015) 0.77